Eli Lilly quits medical technology with Hybritech sale
This article was originally published in Clinica
Eli Lilly has agreed to sell its San Diego-based diagnostics subsidiary Hybritech to Beckman Instruments. The sale brings an end to Lilly's interests in the diagnostics and medical devices field. The deal is expected to close on January 2nd, almost two years after Lilly originally announced it wanted to exit the medtech industry.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.